Last Updated: September 24, 2026

Details for New Drug Application (NDA): 208276

✉ Email this page to a colleague

NDA 208276 describes REMODULIN, which is a drug marketed by United Therap and is included in two NDAs. It is available from one supplier. There are five patents protecting this drug and two Paragraph IV challenges. Additional details are available on the REMODULIN profile page.

The generic ingredient in REMODULIN is treprostinil. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the treprostinil profile page.

Summary for 208276

Tradename:	REMODULIN
Applicant:	United Therap
Ingredient:	treprostinil
Patents:	1

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS, SUBCUTANEOUS			Strength	20MG/20ML (1MG/ML)
Approval Date:	Jul 30, 2018	TE:		RLD:	No
Patent:	9,593,066	Patent Expiration:	Dec 15, 2028	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS, SUBCUTANEOUS			Strength	50MG/20ML (2.5MG/ML)
Approval Date:	Jul 30, 2018	TE:		RLD:	No
Patent:	9,593,066	Patent Expiration:	Dec 15, 2028	Product Flag?		Substance Flag?	Y	Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS, SUBCUTANEOUS			Strength	100MG/20ML (5MG/ML)
Approval Date:	Jul 30, 2018	TE:		RLD:	No
Patent:	9,593,066	Patent Expiration:	Dec 15, 2028	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 208276

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
United Therap	REMODULIN	treprostinil	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	208276-001	Jul 30, 2018	10,076,505	⤷ Start Trial
United Therap	REMODULIN	treprostinil	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	208276-004	Jul 30, 2018	9,713,599	⤷ Start Trial
United Therap	REMODULIN	treprostinil	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	208276-004	Jul 30, 2018	10,076,505	⤷ Start Trial
United Therap	REMODULIN	treprostinil	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	208276-002	Jul 30, 2018	9,713,599	⤷ Start Trial
United Therap	REMODULIN	treprostinil	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	208276-002	Jul 30, 2018	10,076,505	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.